Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Mobile Health for Adherence in Breast Cancer Patients
NCT06112613 · View on ClinicalTrials.gov ↗
Study Summary
This clinical trial compares the use of the connected customized treatment platform (CONCURxP), consisting of using a medication monitoring device called WiseBag along with text message reminders for missed or extra medication events, to enhanced usual care (EUC), where patients only use the WiseBag, to monitor medication adherence in patients with metastatic breast cancer who are taking a CKD4/6 inhibitor. To ensure CDK4/6 inhibitors achieve their full clinical benefit, patients need to take them as prescribed, following a complex treatment schedule. Forgetfulness was the most common reason reported for medication non adherence. Using the WiseBag along with CONCURxP or enhanced usual care may improve medication adherence in patients with metastatic breast cancer who are taking a CKD4/6 inhibitor.
Conditions Studied
Interventions
- OTHER Electronic Health Record Review
- OTHER Interview
- OTHER Health Promotion and Education
- BEHAVIORAL Patient Navigation
- PROCEDURE Health Telemonitoring
Study Locations (20)
California
- Kaiser Permanente-Anaheim — Anaheim
- Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande
- PCR Oncology — Arroyo Grande
- Kaiser Permanente-Baldwin Park — Baldwin Park
- Kaiser Permanente-Bellflower — Bellflower
- Mercy Cancer Center - Carmichael — Carmichael
- Mercy San Juan Medical Center — Carmichael
- Mercy Cancer Center - Elk Grove — Elk Grove
- Kaiser Permanente-Fontana — Fontana
- Kaiser Permanente - Harbor City — Harbor City
- Kaiser Permanente-Irvine — Irvine
- Kaiser Permanente Los Angeles Medical Center — Los Angeles
- Kaiser Permanente West Los Angeles — Los Angeles
- Contra Costa Regional Medical Center — Martinez
Arkansas
- Mercy Hospital Fort Smith — Fort Smith
- NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro — Jonesboro
- CARTI Cancer Center — Little Rock
Arizona
- Kingman Regional Medical Center — Kingman
- Cancer Center at Saint Joseph's — Phoenix
Alaska
- Fairbanks Memorial Hospital — Fairbanks
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 410 participants |
| Start Date | 2024-01-26 |
| Est. Completion | 2027-07-31 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06112613
The ClinicalTrials.gov registry entry for NCT06112613 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 410 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ECOG-ACRIN Cancer Research Group, which has 52 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 4 conditions, with Breast Carcinoma appearing as the primary indexed condition, and to 5 interventions — of which Electronic Health Record Review is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06112613 reports 20 study locations spanning 4 distinct geographic areas — top geographies include California, Arkansas, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06112613 about?
NCT06112613 is a clinical study titled "Mobile Health for Adherence in Breast Cancer Patients". This clinical trial compares the use of the connected customized treatment platform (CONCURxP), consisting of using a medication monitoring device called WiseBag along with text message reminders for missed or extra medication events, to enhanced usual care (EUC), where patients only use the WiseBag...
What is the current status of trial NCT06112613?
This trial is currently recruiting. It is a NA study. The enrollment target is 410 participants. The study started on 2024-01-26. Estimated completion is 2027-07-31.
What conditions does trial NCT06112613 study?
This clinical trial studies the following conditions: Breast Carcinoma, Anatomic Stage IV Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06112613?
The interventions under investigation include: Electronic Health Record Review (OTHER), Interview (OTHER), Health Promotion and Education (OTHER), Patient Navigation (BEHAVIORAL), Health Telemonitoring (PROCEDURE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06112613?
This trial is sponsored by ECOG-ACRIN Cancer Research Group, which has 52 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06112613 being conducted?
This trial has 20 study locations across Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.